
At EPO, Patent Oppositions To High-Priced Gilead Hepatitis C Drug Pile Up
According to a public health advocacy group, there are now as many as 10 oppositions filed at the European Patent Office against the Gilead company's patent on sofosbuvir, a treatment for hepatitis C. The group has compiled a table showing the filings with links to the documents.











